TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19320662
Drug: Vildagliptin monotherapy
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin monotherapy (50 mg twice daily)
Study: 19320662
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin monotherapy (1000 mg twice daily)
Study: 19320662
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus high-dose metformin combination therapy
Study: 19320662
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus low-dose metformin combination therapy
Study: 8021335
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (M-5041T), 6 mg applied for 3 days
Study: 8021335
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (Catapres), 0.075 mg every 12 hours for 3 days
Study: 8021335
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (M-5041T)
Study: 8021335
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (Catapres)
Study: 2739347
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no preoperative chemotherapy)
Study: 23999956
Drug: 6-session intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-session intervention including trauma-focused treatments (psychoeducation, cognitive restructuring, progressive muscle relaxation, development of trauma narrative) and infant redefinition
Study: 20615632
Drug: Ultrahigh PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahigh PSA levels (≥50 ng/ml)
Study: 16765182
Drug: No BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BCG treatment (control group)
Study: 16765182
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy with maintenance treatment
Study: 16765182
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy for papillary carcinoma
Study: 16765182
Drug: BCG plus
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG plus chemotherapy/immunotherapy
Study: 9552503
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during excimer laser angioplasty
Study: 31479530
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus reuteri lozenges, used twice-daily for 28 days as an adjunct to NSPT
Study: 31479530
Drug: Placebo lozenges,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges, used twice-daily for 28 days as an adjunct to NSPT
Study: 31479530
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus reuteri lozenges
Study: 28222678
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg (Group D1)
Study: 28222678
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg/kg (Group D2)
Study: 19547873
Drug: Isoniazid chemoprophylaxis
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid chemoprophylaxis (300 mg/day) for six months
Study: 16787996
Drug: Bias-adjusted parameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bias-adjusted parameter estimator for the treatment coefficient
Study: 16787996
Drug: Point estimator
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point estimator for treatment effect
Study: 11642624
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of oral acyclovir treatment (80 mg/kg/day up to a maximum of 3,200 mg/day in four divided doses) starting within 24 hours of rash onset (Group A)
Study: 11642624
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of acyclovir treatment starting on the first day of rash (Group B1)
Study: 11642624
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of acyclovir treatment starting on the second day of rash (Group B2)
Study: 11642624
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A subjects (acyclovir treatment within 24 hours of rash onset)
Study: 9374086
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2 at intervals of 30 minutes, 4 hours, and 24 hours every 3 weeks
Study: 9374086
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2
Study: 23148731
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lacosamide oral tablet
Study: 23148731
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lacosamide oral syrup
Study: 23148731
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of tablet and syrup formulations
Study: 23148731
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of lacosamide
Study: 22130748
Drug: Supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised treatment in out-patients for schizophrenia (STOPS)
Study: 19387363
Drug: Normoxia (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoxia (placebo group inhaled normoxic air)
Study: 3317337
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and nifedipine
Study: 29420951
Drug: 5‐fluorouracil (subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (subconjunctival injection)
Study: 26660000
Drug: Both techniques
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both techniques (DGG-L and DGG-B)
Study: 22901422
Drug: Daily pin
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pin site care
Study: 15882256
Drug: AT1R blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT1R blocker (losartan)
Study: 15882256
Drug: AT1R blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT1R blocker (candesartan)
Study: 15882256
Drug: AT1R blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT1R blocker treatment
Study: 10411764
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam preoperatively with sevoflurane
Study: 25851802
Drug: Aprepitant (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (80 mg for 15-40 kg, 125 mg for 41-65 kg on day 1, 80 mg for days 2-3)
Study: 17026492
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg/day for 12 weeks
Study: 15126259
Drug: Chest radiography
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest radiography alone or in combination with sputum cytologic examination
Study: 11404278
Drug: Alcohol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (total dose of 256 g)
Study: 8485531
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (D1) of Tacrine (40 mg/day)
Study: 8485531
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (D2) of Tacrine (80 mg/day)
Study: 3315265
Drug: Euphyllin CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin CR (642 mg total daily dose, 1/3 in the morning and 2/3 in the evening, evening dose at 2200 hr)
Study: 3315265
Drug: Afonilum Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afonilum Retard (500 mg total daily dose, equal amounts in the morning and evening, evening dose at 2000 hr)
Study: 27422692
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) - 20 mL bupivacaine/20 mL saline, intraoperative local infiltration
Study: 16184062
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg midazolam
Study: 16184062
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg midazolam
Study: 25365612
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg midazolam
Study: 16184062
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (1.0 mg/kg midazolam)
Study: 12626890
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) users
Study: 12626890
Drug: Reverse transcriptase
Normalized name: Reverse transcriptase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse transcriptase inhibitor (RTI) users
Study: 12626890
Drug: No antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiretroviral therapy (ART) users
Study: 9295498
Drug: Multi-agent controlling
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-agent controlling method to promote milk secretion
Study: 1852848
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment program (parent training and training of boys for social skills, fantasy play, and television viewing)
Study: 22349746
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 15 mg/kg
Study: 21296248
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 1.0 mg/kg
Study: 19577902
Drug: Intranasal packing
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal packing with septal splints and antibiotic meshes
Study: 17074346
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) (oE(2), 1 mg/d)
Study: 17074346
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) (tE(2), 0.05 mg/d)
Study: 3661439
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg once or twice daily for 6 weeks
Study: 3661439
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg plus amiloride 2.5 mg once or twice daily for 6 weeks
Study: 3661439
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg plus hydrochlorothiazide 25 mg and amiloride 2.5 mg
Study: 3661439
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose nisoldipine and low-dose diuretic
Study: 28103616
Drug: l-Lysine (4.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Lysine (4.95 g/day orally)
Study: 25742208
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking
Study: 25742208
Drug: Daily/targeted placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily/targeted placebo
Study: 21234852
Drug: Prednisone (Cor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (Cor, 50 mg/day for 7 days)
Study: 18259123
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (titrated to 100 mg/d at 4 weeks)
Study: 18259123
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 50 mg (titrated to 100 mg/d at 4 weeks)
Study: 16907691
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment (efficacy data from RCT)
Study: 14570732
Drug: Cluster analysis
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster analysis based on rectal sensitivity and psychological symptoms
Study: 1347230
Drug: H1- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1- and H2-receptor antagonists + Atracurium 0.6 mg kg‐1
Study: 4007349
Drug: Digoxin therapy
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin therapy (Group A)
Study: 17014513
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Group B)
Study: 24678758
Drug: Manual orthopaedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual orthopaedic therapy with proprioception training
Study: 17666597
Drug: IVIG 2
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 2 g/kg/wk (group A)
Study: 17666597
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg/wk plus prednisone 0.5 mg/kg/d (group B)
Study: 11823672
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL (100 mg once daily)
Study: 9935096
Drug: LPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPA therapy at 20 J/cm2, double pulsed at a repetition rate of one Hz
Study: 9935096
Drug: LPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPA therapy at 20 J/cm2, single pulsed with a pulse duration of 5 msec followed by 23.4% hypertonic saline sclerotherapy
Study: 8785378
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg selegiline tablet
Study: 8785378
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg selegiline solution
Study: 8785378
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both dosage forms
Study: 8785378
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (tablet and solution)
Study: 27999018
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (0.3‐0.6 mg/kg twice daily) with ART (tenofovir, emtricitabine and lopinavir/ritonavir) for 8 weeks
Study: 23263720
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a plus ribavirin (135‐180 µg subcutaneously/week and 800‐1200 mg/day orally)
Study: 23263720
Drug: interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon alfa‐2b plus ribavirin (300‐500 million units, once every other day and 800‐1200 mg/day)
Study: 14719195
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every other week
Study: 15146409
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg subcutaneously every week
Study: 10467196
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg twice daily, n = 14)
Study: 7601400
Drug: Bolus somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus somatostatin (250 micrograms injection followed by 250 micrograms/h infusion)
Study: 7601400
Drug: Continuous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous somatostatin (250 micrograms/h infusion)
Study: 7601400
Drug: Continuous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous somatostatin (500 micrograms/h infusion)
Study: 2210972
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg at 12-hour intervals (30 subjects)
Study: 2210972
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg at 12-hour intervals (24 subjects)
Study: 2210972
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg at 12-hour intervals for three days (23 subjects with uncomplicated UTI)
Study: 31331065
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed whey formula with 1.8 g protein/100 kcal (pHF1.8)
Study: 31331065
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed whey formula with 2.27 g protein/100 kcal (pHF2.27)
Study: 31331065
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed whey formula with 2.0 g protein/100 kcal (pHF2.0)
Study: 28698351
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intranasal ketamine
Study: 28698351
Drug: Volume-matched intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched intranasal normal saline (placebo)
Study: 28698351
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic therapy (for all participants)
Study: 23807349
Drug: Brimonidine-timolol fixed
Normalized name: brimonidine / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine-timolol fixed combination therapy (FCBT)
Study: 23807349
Drug: Dorzolamide-timolol fixed
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol fixed combination therapy (FCDT)
Study: 19523908
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (0.1 ml of trivalent inactivated influenza vaccine, 3 microg of hemagglutinin per strain)
Study: 19523908
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (0.25 ml of trivalent inactivated influenza vaccine, 7.5 microg of hemagglutinin per strain)
Study: 8070610
Drug: Lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-20 mg/day)
Study: 27864832
Drug: Colistin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (2.5 million IU intravenous dose)
Study: 21791965
Drug: hm gamma-PGA
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: hm gamma-PGA treatment in rats (NFP or HFP) for 4 weeks
Study: 21791965
Drug: hm gamma-PGA
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: hm gamma-PGA supplementation (150 mg/day) in humans for 8 weeks
Study: 19332187
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months clopidogrel therapy after DES implantation
Study: 19332187
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months clopidogrel therapy after DES implantation
Study: 15190231
Drug: SR 142801
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 142801 (NK3 receptor antagonist)
Study: 15190231
Drug: SR 48692
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48692 (neurotensin receptor antagonist)
Study: 15190231
Drug: SR 141716
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 141716 (cannabinoid receptor antagonist)
Study: 2871849
Drug: Atracurium (0.135-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.135-0.5 mg kg‐1)
Study: 2871849
Drug: Vecuronium (0.02-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.02-0.1 mg kg‐1)
Study: 2871849
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of equipotent doses of atracurium and vecuronium
Study: 31210635
Drug: Sound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound therapy (maskers)
Study: 31210635
Drug: No sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sound therapy (control)
Study: 22711499
Drug: 238 g
Normalized name: AVOBENZONE 3.371 g in 112.38 g / OXYBENZONE 6.743 g in 112.38 g / OCTINOXATE 8.429 g in 112.38 g / HOMOSALATE 11.238 g in 112.38 g / OCTISALATE 5.619 g in 112.38 g TOPICAL CREAM [Advanced Sun Resistance SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 238 g PEG + 1.9 L Gatorade
Study: 22711499
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of PEG-ELS
Study: 18721566
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) kallikrein inhibiting units (KIU) loading dose, 0.5 x 10(6) KIU/hour)
Study: 11954952
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no colforsin treatment)
Study: 10623332
Drug: Nebuhaler pressurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler pressurized metered dose inhaler (pMDI)
Study: 7494824
Drug: Pure water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure water (control solution)
Study: 7494824
Drug: Mannitol 10
Normalized name: mannitol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 10 g/200 ml